SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?


To: Ariella who wrote (1039)7/17/1998 8:46:00 PM
From: crysball  Read Replies (3) | Respond to of 1491
 
Continuing to accumulate at 'bargain basement' prices on what appears to be continuing positive information noted by the more erudite posters on PARS [SI & Yahoo Finance] message boards.

Perhaps PARS management will think again (and plan better) before they back themselves into another private placement [such as they did with Castle Creek] which created an on-going market overhang. Would seriously doubt they envisioned the impact of this decision, when they made it.

B & L as well as Castle Creek both cut deals which enabled PARS to survive, but at a horrible cost which continue to place a drag on PARS stock price.

Will PARS management continue to drink their own bathwater?...........hopefully they won't count their chickens [Alrex & Lotemax revenue stream ] , before they hatch, since we are still filling an inventory pipeline, and the continuing revenue stream pattern from new and repeat prescriptions may take some time to develop.

It would be nice if we could get reports from a stockholder who has access to new prescriptions written databanks.

I'm very bullish on the products and Dr. Aviv's brilliant virtual business model. However, PARS management has a repetitive history of their "eyes being bigger than their stomach" .

Hopefully, the new CFO can keep their cash burn under control, and the scientific types foucsed on the business task(s) at haand.

Best Regards,